Common adverse reactions are typical for the class of nitrogen mustards, and include nausea, fatigue, vomiting, diarrhea, fever, constipation, loss of appetite, cough, headache, unintentional weight loss, difficulty breathing, rashes, and stomatitis, as well as immunosuppression, anemia, and low platelet counts. Notably, this drug has a low incidence of hair loss (alopecia) unlike most other chemotherapy drugs. Warning<unk>  solution is not compatible with Closed System Transfer Devices (CSTD) Situation: *Most CSTD vendors have adapted their system to become compatible. * FDA issued a warning on March 11, 2015 not to use<unk>  solution with CSTDs, adapters and syringes which contain either polycarbonate or acrylonitrile-butadiene-styrene (ABS) due to the incompatibility with N,N-dimethylacetamide (DMA). Background: * PhaSealR & SpirosR CSTDs contain either polycarbonate or ABS can dissolve when coming into contact with<unk>  (which contains DMA). Assessment: * This can lead to device failure, possible product contamination, and potential serious adverse health consequences, including skin reactions in health care professionals preparing and administering this product and the risk of small blood vessel blockage in patients. Recommendations: * Immediately, stop using all PhaSealR &/or SpirosR products including adapters when preparing & administering<unk> . * Only use polypropylene syringes with<unk> . These syringes are translucent in appearance. * Continue to use all universal PPE & safety precautions for hazardous drugs when preparing & administering<unk> .
Bendamustine
Lomustine
Carmustine
Mannomustine
Ifosfamide
Normustine
Vincristine
Busulfan